JUN 23, 2018 5:31 AM PDT

Algorithm-Based Blood Test Diagnoses Autism

WRITTEN BY: Kara Marker

As a developmental disorder, autism spectrum disorders (ASD) can be diagnosed as early as 18 to 24 months of age, but often the diagnosis does not come until a child is four years old. This is due to a dependence on clinical observations, but a new Rensselaer Polytechnic Institute shows the promising opportunity for an algorithm-based blood test to help clinicians make an ASD diagnosis as early as possible.

One year after researchers published their work on a physiological test for autism, a follow-up study confirms its exceptional success in assessing whether a child is on the autism spectrum. Credit: Rensselaer

ASD is defined as a developmental disorder affecting communication and behavior, with those affected having difficulty in various social situations:

  • Interaction with other people
  • Restricted interests and repetitive behaviors
  • Inability to function normally in school, work, and other social contexts

Just under two percent of children are diagnosed with autism, and when children are diagnosed early in life, they receive the opportunity to engage in early intervention services. Treatment for ASD can be used for relieving irritability, aggression, repetitive behavior, hyperactivity, attention problems and anxiety and depression. Children diagnosed with ASD can also benefit from behavioral, psychological, and educational therapy.

Lead author Juergen Hahn developed his algorithm-based test not to take over as the reigning technique for diagnosing ASD, but to accompany a clinician’s diagnostic process to diagnose children as early as possible. The test is based on specific metabolites identifiable in a blood sample. Hahn says the test is “extremely promising.”

As opposed to looking for just one major biomarker indicative of ASD, Hahn set out to look for a panel of metabolites that were linked to two cellular pathways already associated with ASD: the methionine cycle and the transsulfuration pathway. His 2017 study included data from 149 people, half of which had already been diagnosed with ASD.

Hahn analyzed data on 24 metabolites related to the two pathways and used his results to design a predictive algorithm. Then, he used that algorithm to correctly identify 96.1 percent of all typically developing participants and 97.6 with an ASD diagnosis.

In the new study, Hahn tested the algorithm in a fresh dataset, containing data from 154 children with ASD. The predictive algorithm correctly identified autism with 88 percent accuracy. The reason for the missing percentage points? In the new study, only 22 out of the 24 original metabolites were included.

"The most meaningful result is the high degree of accuracy we are able to obtain using this approach on data collected years apart from the original dataset," Hahn concluded. "This is an approach that we would like to see move forward into clinical trials and ultimately into a commercially available test."

The present study was published in the journal Bioengineering & Translational Medicine.

Sources: National Institute of Mental Health, Rensselaer Polytechnic Institute

 

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 29, 2020
Cannabis Sciences
Hemp 10 Years from Now
OCT 29, 2020
Hemp 10 Years from Now
The hemp industry has experienced major growth in recent years, largely due to legalization in many US states. Today, th ...
NOV 16, 2020
Clinical & Molecular DX
How the CRISPR-based COVID Microlab Can Intercept the Pandemic
NOV 16, 2020
How the CRISPR-based COVID Microlab Can Intercept the Pandemic
The demand for diagnostic technologies to track COVID-19 infections and control community spread of the disease has only ...
NOV 18, 2020
Clinical & Molecular DX
Nerve Damage as a Prognostic Marker for Rare Autoimmune Disease
NOV 18, 2020
Nerve Damage as a Prognostic Marker for Rare Autoimmune Disease
Researchers have identified a new prognostic biomarker for Guillain-Barré syndrome (GBS), a rare autoimmune disor ...
NOV 25, 2020
Cancer
Using RNA to Diagnose HPV Associated Cancer
NOV 25, 2020
Using RNA to Diagnose HPV Associated Cancer
Diagnostic tools are critical to modern medicine. They might be less exciting than a good therapy or drug, but doctors a ...
DEC 16, 2020
Clinical & Molecular DX
Gene Marker PACS a Punch for Cervical Cancer Treatments
DEC 16, 2020
Gene Marker PACS a Punch for Cervical Cancer Treatments
In cervical cancer, mutations in healthy cells cause cells to grow and multiply uncontrollably, invading surrounding tis ...
FEB 17, 2021
Clinical & Molecular DX
Urine Test Bypasses the Need for Prostate Biopsies
FEB 17, 2021
Urine Test Bypasses the Need for Prostate Biopsies
Researchers have created a urine test for prostate cancer that could make unnecessary biopsies a thing of the past. The ...
Loading Comments...